Earle Burgess: Initial results from a small pilot study in late mCRPC where there are limited to no effective treatment options available

Earle Burgess, Genitourinary Oncologist at Atrium Health Levine Cancer, shared on LinkedIn:

“Enfortumab vedotin is a blockbuster drug in bladder cancer.
Looks like it might have activity in prostate cancer as well.

Initial results from a small pilot study in late mCRPC where there are limited to no effective treatment options available.

Large unmet need in this setting, so this could be a big deal if confirmed.”

Read Further.
Source: Earle Burgess/LinkedIn